Vaccines to combat the neglected tropical diseases

Immunological Reviews

Volumn 239, Issue 1, 2011, Pages 237-270

  Bethony, Jeffrey M ^a   Cole, Rhea N ^b   Guo, Xiaoti ^c   Kamhawi, Shaden ^d   Lightowlers, Marshall W ^e   Loukas, Alex ^f   Petri, William ^g   Reed, Steven ^b   Valenzuela, Jesus G ^d   Hotez, Peter J ^a,h  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b Infectious Diseases Research Institute   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f JAMES COOK UNIVERSITY   (Australia)

^g UNIVERSITY OF VIRGINIA   (United States)

^h SABIN VACCINE INSTITUTE   (United States)

Author keywords

Neglected tropical diseases; Parasitic vaccines; Tropical diseases; Vaccines

Indexed keywords

ALBENDAZOLE; CYSTICERCOSIS VACCINE; ECHINOCOCCOSIS VACCINE; ENTERIC PROTOZOA VACCINE; HOOKWORM VACCINE; LEISHMANIA VACCINE; MEBENDAZOLE; PRAZIQUANTEL; RECOMBINANT VACCINE; SCHISTOSOMIASIS VACCINE; SH28 GST VACCINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; AFRICA SOUTH OF THE SAHARA; AMEBIASIS; ARTICLE; ASCARIASIS; CENTRAL AMERICA; CYSTICERCOSIS; DRUG FORMULATION; ECHINOCOCCOSIS; EDUCATIONAL STATUS; HOOKWORM INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; LEISHMANIASIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SALIVA; SCHISTOSOMIASIS; SOCIOECONOMICS; SOUTH AMERICA; SOUTH ASIA; SOUTHEAST ASIA; TRICHOMONIASIS; TROPICAL DISEASE; VACCINATION;

ANIMALS; DISEASE MODELS, ANIMAL; HELMINTHIASIS; HUMANS; INTESTINAL DISEASES, PARASITIC; NEGLECTED DISEASES; PARASITIC DISEASES; POVERTY AREAS; PROTOZOAN INFECTIONS; PROTOZOAN VACCINES; TROPICAL MEDICINE; VACCINES;

EID: 78650575238     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2010.00976.x     Document Type: Article

References (287)

1. Hotez P. Forgotten People, Forgotten Diseases: The Neglected Tropical Diseases and their Impact on Global Health and Development. Washington, DC: American Society for Microbiology Press, 2008.
2. Collier P. The Bottom Billion: Why the Poorest Countries Are Failing and What Can Be Done About It. Oxford: Oxford University Press, 2007.
3. Hotez PJ, Ferris MT. The antipoverty vaccines. Vaccine 2006;24:5787-5799.
4. Hotez P. Combating parasitic diseases in innovative developing countries by reverse vaccinology. Parasite Immunol 2006;28:242-243.
5. Hotez PJ. A plan to defeat neglected tropical diseases. Sci Am 2010;302:90-94.
6. Hotez PJ, et al. Control of neglected tropical diseases. N Engl J Med 2007;357:1018-1027.
7. Musgrove P, Hotez PJ. Turning neglected tropical diseases into forgotten maladies. Health Aff (Millwood) 2009;28:1691-1706.
8. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009;373:1570-1575.
9. Hotez PJ, Brown AS. Neglected tropical disease vaccines. Biologicals 2009;37:160-164.
10. Hotez PJ, Kamath A. Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 2009;3:e412.
11. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 2006;3:e102.
12. King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop 2010;113:95-104.
13. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 2005;365:1561-1569.
14. Hotez PJ, Brooker S, Bethony JM, Bottazzi ME, Loukas A, Xiao S. Hookworm infection. N Engl J Med 2004;351:799-807.
15. Sakti H, et al. Evidence for an association between hookworm infection and cognitive function in Indonesian school children. Trop Med Int Health 1999;43:322-334.
16. Jukes MC, et al. Heavy schistosomiasis associated with poor short-term memory and slower reaction times in Tanzanian schoolchildren. Trop Med Int Health 2002;7:104-117.
17. Miguel E, Kremer M. Worms: identifying impacts on education and health in the presence oof treatment externalities. Econometrica 2004;72:159-217.
18. Bleakley H. Disease and development: evidence from hookworm eradication in the American South. Q J Economics 2007;122:73-117.
19. Hotez PJ. Empowering women and improving female reproductive health through control of neglected tropical diseases. PLoS Negl Trop Dis 2009;3:e559.
20. Brooker S, Hotez PJ, Bundy DA. Hookworm-related anaemia among pregnant women: a systematic review. PLoS Negl Trop Dis 2008;2:e291.
21. Kjetland EF, et al. Association between genital schistosomiasis and HIV in rural Zimbabwean women. AIDS 2006;20:593-600.
22. Garcia HH, Del Brutto OH. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005;4:653-661.
23. de Silva NR, Brooker S, Hotez PJ, Montresor A, Engels D, Savioli L. Soil-transmitted helminth infections: updating the global picture. Trends Parasitol 2003;19:547-551.
24. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006;6:411-425.
25. WHO. Dracunculiasis eradication. Wkly Epidemiol Rec 2008;83:159-167.
26. Eckert J, Gemmell MA, Meslin F-X, Pawlowski ZS. WHO/OIE Manual on Echinococcosis in Humans and Animals: A Public Health Problem of Global Concern. Paris: WHO/FAO, 2001.
27. Murrell KDE. WHO/FAO/OIE Guidelines for the Surveillance, Prevention and Control of Taeniasis/Cysticercosis. Paris: OIE/WHO/ FAO, 2005.
28. WHO. Human African trypanosomiasis (sleeping sickness). Wkly Epidemiol Rec 1999;74:245-246.
29. Reithinger R, Brooker S, Kolaczinski JH. Visceral leishmaniasis in eastern Africa - current status. Trans R Soc Trop Med Hyg 2007;101:1169-1170.
30. Stauffer W, Abd-Alla M, Ravdin JI. Prevalence and incidence of Entamoeba histolytica infection in South Africa and Egypt. Arch Med Res 2006;37:266-269.
31. Hotez PJ, Ehrenberg JP. Escalating the global fight against neglected tropical diseases through interventions in the Asia Pacific region. Adv Parasitol 2010;72:31-53.
32. Sripa B, et al. Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos. Acta Trop. 2010;doi:.
33. Sripa B, et al. Liver fluke induces cholangiocarcinoma. PLoS Med 2007;4:e201.
34. Wang LD, et al. A strategy to control transmission of Schistosoma japonicum in China. N Engl J Med 2009;360:121-128.
35. Craig PS, Liu D, Ding Z. Hydatid disease in China. Parasitol Today 1991;7:46-50.
36. Gautam VP. Treatment of leprosy in India. J Postgrad Med 2009;55:220-224.
37. Bethony J, et al. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 2006;367:1521-1532.
38. Perera M, Whitehead M, Molyneux D, Weerasooriya M, Gunatilleke G. Neglected patients with a neglected disease? A qualitative study of lymphatic filariasis PLoS Negl Trop Dis 2007;1:e128.
39. Joshi A, et al. Can visceral leishmaniasis be eliminated from Asia?. J Vector Borne Dis 2008;45:105-111.
40. Bansal D, Malla N, Mahajan RC. Drug resistance in amoebiasis. Indian J Med Res 2006;123:115-118.
41. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2008;2:e300.
42. Hotez P. Neglected diseases amid wealth in the United States and Europe. Health Aff (Millwood) 2009;28:1720-1725.
43. Hotez PJ. The giant anteater in the room: Brazil's neglected tropical diseases problem. PLoS Negl Trop Dis 2008;2:e177.
44. Franco-Paredes C, et al. Chagas disease: an impediment in achieving the Millennium Development Goals in Latin America. BMC Int Health Hum Rights 2007;7:7.
45. Beyrer C, Villar JC, Suwanvanichkij V, Singh S, Baral SD, Mills EJ. Neglected diseases, civil conflicts, and the right to health. Lancet 2007;370:619-627.
46. Ko AI, Goarant C, Picardeau M. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Microbiol 2009;7:736-747.
47. Hotez PJ. Neglected diseases and poverty in "The Other America": the greatest health disparity in the United States? PLoS Negl Trop Dis 2007;1:e149.
48. Jannin J, Louis FJ, Lucas P, Simarro PP. [Control of human African trypanosomiasis: back to square one]. Med Trop (Mars) 2001;61:437-440.
49. Hotez PJ. Mass drug administration and integrated control for the world's high-prevalence neglected tropical diseases. Clin Pharmacol Ther 2009;85:659-664.
50. Molyneux DH, Hotez PJ, Fenwick A. "Rapid-impact interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med 2005;2:e336.
51. Hotez PJ, Pecoul B. "Manifesto" for advancing the control and elimination of neglected tropical diseases. PLoS Negl Trop Dis 2010;4:e718.
52. Hotez PJ, Bethony JM, Oliveira SC, Brindley PJ, Loukas A. Multivalent anthelminthic vaccine to prevent hookworm and schistosomiasis. Expert Rev Vaccines 2008;7:745-752.
53. Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J. Helminth infections: the great neglected tropical diseases. J Clin Invest 2008;118:1311-1321.
54. Heath DD, Jensen O, Lightowlers MW. Progress in control of hydatidosis using vaccination - a review of formulation and delivery of the vaccine and recommendations for practical use in control programmes. Acta Trop 2003;85:133-143.
55. Lightowlers MW. Eradication of Taenia solium cysticercosis: a role for vaccination of pigs. Int J Parasitol 2010;40:1183-1192.
56. Loukas A, Bethony J, Brooker S, Hotez P. Hookworm vaccines: past, present, and future. Lancet Infect Dis 2006;6:733-741.
57. McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008;21:225-242.
58. Koizumi N, Watanabe H. Leptospirosis vaccines: past, present, and future. J Postgrad Med 2005;51:210-214.
59. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol 2005;21:244-249.
60. Mora M, Veggi D, Santini L, Pizza M, Rappuoli R. Reverse vaccinology. Drug Discov Today 2003;8:459-464.
61. Tran MH, et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006;12:835-840.
62. Lightowlers MW. Cestode vaccines: origins, current status and future prospects. Parasitology 2006;133(Suppl):S27-S42.
63. Monsalve RI, Lu G, King TP. Expression of yellow jacket and wasp venom Ag5 allergens in bacteria and in yeast. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1999;(93):181-188.
64. Mett V, Farrance CE, Green BJ, Yusibov V. Plants as biofactories. Biologicals 2008;36:354-358.
65. Jariwala AR, et al. Potency testing for the experimental Na-GST-1 hookworm vaccine. Expert Rev Vaccines 2010;9:1219-1230.
66. International Conference on Harmonization. Q6B specifications test procedures and acceptance criteria for biotechnological/biological products. 1999.
67. Hendriksen CF. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement. Expert Rev Vaccines 2009;8:313-322.
68. Giersing BK, Dubovsky F, Saul A, Denamur F, Minor P, Meade B. Potency assay design for adjuvanted recombinant proteins as malaria vaccines. Vaccine. 2006;24:4264-4270.
69. Arciniega J. What's in a name? The meaning of the term "potency" as applied to immunobiologics for human use and its implications for alternatives and validation Dev Animal Vet Sci 2000;31:979-986.
70. Fujiwara RT, Geiger SM, Bethony J, Mendez S. Comparative immunology of human and animal models of hookworm infection. Parasite Immunol 2006;28:285-293.
71. Miller TA. Vaccination against the canine hookworm diseases. Adv Parasitol 1971;9:153-183.
72. Miller TA. The diagnosis of hookworm disease. Mod Vet Pract 1974;55:706-709.
73. Miller TA. Industrial development and field use of the canine hookworm vaccine. Adv Parasitol 1978;16:333-342.
74. Xue J, et al. Necator americanus: optimization of the golden hamster model for testing anthelmintic drugs. Exp Parasitol 2005;111:219-223.
75. Cutts FT, Enwere G, Zaman SM, Yallop FG. Operational challenges in large clinical trials: examples and lessons learned from the Gambia pneumococcal vaccine trial. PLoS Clin Trials 2006;1:e16.
76. Krosin MT, Klitzman R, Levin B, Cheng J, Ranney ML. Problems in comprehension of informed consent in rural and peri-urban Mali, West Africa. Clin Trials 2006;3:306-313.
77. Sudore RL, Landefeld CS, Williams BA, Barnes DE, Lindquist K, Schillinger D. Use of a modified informed consent process among vulnerable patients: a descriptive study. J Gen Intern Med 2006;21:867-873.
78. Chen X, et al. Differences in perception of dysentery and enteric fever and willingness to receive vaccines among rural residents in China. Vaccine 2006;24:561-571.
79. Pack R, et al. Willingness to be vaccinated against shigella and other forms of dysentery: a comparison of three regions in Asia. Vaccine. 2006;24:485-494.
80. Kaljee LM, Pack R, Pach A, Nyamete A, Stanton BF. Sociobehavioural research methods for the introduction of vaccines in the Diseases of the Most Impoverished Programme. J Health Popul Nutr 2004;22:293-303.
81. Gazzinelli MF, et al. Health education through analogies: preparation of a community for clinical trials of a vaccine against hookworm in an endemic area of Brazil. PLoS Negl Trop Dis 2010;4:e749.
82. Maizels RM. Infections and allergy - helminths, hygiene and host immune regulation. Curr Opin Immunol 2005;17:656-661.
83. Maizels RM, Balic A, Gomez-Escobar N, Nair M, Taylor MD, Allen JE. Helminth parasites - masters of regulation. Immunol Rev 2004;201:89-116.
84. Maizels RM, Holland MJ, Falcone FH, Zang XX, Yazdanbakhsh M. Vaccination against helminth parasites - the ultimate challenge for vaccinologists? Immunol Rev 1999;171:125-147.
85. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. Science 2002;296:490-494.
86. Erb KJ. Helminths, allergic disorders and IgE-mediated immune responses: where do we stand? Eur J Immunol 2007;37:1170-1173.
87. Leonardi-Bee J, Pritchard D, Britton J. Asthma and current intestinal parasite infection: systematic review and meta-analysis. Am J Respir Crit Care Med 2006;174:514-523.
88. Goud GN, et al. Expression of the Necator americanus hookworm larval antigen Na-ASP-2 in Pichia pastoris and purification of the recombinant protein for use in human clinical trials. Vaccine 2005;23:4754-4764.
89. Goud GN, et al. Cloning, yeast expression, isolation, and vaccine testing of recombinant Ancylostoma-secreted protein (ASP)-1 and ASP-2 from Ancylostoma ceylanicum. J Infect Dis 2004;189:919-929.
90. Hawdon JM, Narasimhan S, Hotez PJ. Ancylostoma secreted protein 2: cloning and characterization of a second member of a family of nematode secreted proteins from Ancylostoma caninum. Mol Biochem Parasitol 1999;99:149-165.
91. Bethony J, et al. Antibodies against a secreted protein from hookworm larvae reduce the intensity of hookworm infection in humans and vaccinated laboratory animals. FASEB J 2005;19:1743-1745.
92. Bethony JM, et al. Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults. Vaccine 2008;26:2408-2417.
93. Chan MS. The global burden of intestinal nematode infections - fifty years on. Parasitol Today 1997;13:438-443.
94. Hotez PJ, Bethony J, Bottazzi ME, Brooker S, Diemert D, Loukas A. New technologies for the control of human hookworm infection. Trends Parasitol 2006;22:327-331.
95. Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 2008;299:1937-1948.
96. Albonico M, Bickle Q, Ramsan M, Montresor A, Savioli L, Taylor M. Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull World Health Organ 2003;81:343-352.
97. Albonico M, et al. Rate of reinfection with intestinal nematodes after treatment of children with mebendazole or albendazole in a highly endemic area. Trans R Soc Trop Med Hyg 1995;89:538-541.
98. Bethony JM, Loukas A, Hotez PJ, Knox DP. Vaccines against blood-feeding nematodes of humans and livestock. Parasitology 2006;133(Suppl):S63-S79.
99. Diemert DJ, Bethony JM, Hotez PJ. Hookworm vaccines. Clin Infect Dis 2008;46:282-288.
100. Hotez PJ, Bethony JM, Diemert DJ, Pearson M, Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 2010;8:814-826.
101. Crompton DW. The public health importance of hookworm disease. Parasitology 2000;121(Suppl):S39-S50.
102. Loukas A, et al. Vaccination with recombinant aspartic hemoglobinase reduces parasite load and blood loss after hookworm infection in dogs. PLoS Med 2005;2:e295.
103. Pearson MS, et al. An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection. FASEB J 2009;23:3007-3019.
104. Pearson MS, et al. Neutralizing antibodies to the hookworm hemoglobinase Na-APR-1: implications for a multivalent vaccine against hookworm infection and schistosomiasis. J Infect Dis 2010;201:1561-1569.
105. Ranjit N, et al. Proteolytic degradation of hemoglobin in the intestine of the human hookworm Necator americanus. J Infect Dis 2009;199:904-912.
106. Xiao S, et al. The evaluation of recombinant hookworm antigens as vaccines in hamsters (Mesocricetus auratus) challenged with human hookworm, Necator americanus. Exp Parasitol 2008;118:32-40.
107. Zhan B, et al. Biochemical characterization and vaccine potential of a heme-binding glutathione transferase from the adult hookworm Ancylostoma caninum. Infect Immun 2005;73:6903-6911.
108. Zhan B, et al. Molecular cloning, biochemical characterization, and partial protective immunity of the heme-binding glutathione S-transferases from the human hookworm Necator americanus. Infect Immun 2010;78:1552-1563.
109. Asojo OA, et al. X-ray structures of Na-GST-1 and Na-GST-2 two glutathione S-transferase from the human hookworm Necator americanus. BMC Struct Biol 2007;7:42.
110. Fenwick A. Waterborne infectious diseases - could they be consigned to history? Science 2006;313:1077-1081.
111. Hotez P, Ottesen E, Fenwick A, Molyneux D. The neglected tropical diseases: the ancient afflictions of stigma and poverty and the prospects for their control and elimination. Adv Exp Med Biol 2006;582:23-33.
112. Bergquist NR, Leonardo LR, Mitchell GF. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach? Trends Parasitol 2005;21:112-117.
113. Bethony JM, Diemert DJ, Oliveira SC, Loukas A. Can schistosomiasis really be consigned to history without a vaccine? Vaccine 2008;26:3373-3376.
114. Richter J. The impact of chemotherapy on morbidity due to schistosomiasis. Acta Trop 2003;86:161-183.
115. Campagne G, Garba A, Barkire H, Vera C, Sidiki A, Chippaux JP. [Continued ultrasonic follow-up of children infected with Schistosoma haematobium after treatment with praziquantel]. Trop Med Int Health 2001;6:24-30.
116. Hatz CF, et al. Evolution of Schistosoma haematobium-related pathology over 24 months after treatment with praziquantel among school children in southeastern Tanzania. Am J Trop Med Hyg 1998;59:775-781.
117. Botros S, Sayed H, Amer N, El-Ghannam M, Bennett JL, Day TA. Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. Int J Parasitol 2005;35:787-791.
118. Doenhoff MJ, Kusel JR, Coles GC, Cioli D. Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans R Soc Trop Med Hyg 2002;96:465-469.
119. Ismail M, et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 1999;60:932-935.
120. Hagan P, Appleton CC, Coles GC, Kusel JR, Tchuem-Tchuente LA. Schistosomiasis control: keep taking the tablets. Trends Parasitol 2004;20:92-97.
121. Utzinger J, Xiao SH, Tanner M, Keiser J. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 2007;8:105-116.
122. Fulford AJ, et al. Water contact observations in Kenyan communities endemic for schistosomiasis: methodology and patterns of behaviour. Parasitology 1996;113:223-241.
123. Woolhouse ME, Hagan P. Seeking the ghost of worms past. Nat Med 1999;5:1225-1227.
124. Fulford AJ, Webster M, Ouma JH, Kimani G, Dunne DW. Puberty and age-related changes in susceptibility to schistosome infection. Parasitol Today 1998;14:23-26.
125. Woolhouse ME. Patterns in parasite epidemiology: the peak shift. Parasitol Today 1998;14:428-434.
126. Caldas IR, et al. Susceptibility and resistance to Schistosoma mansoni reinfection: parallel cellular and isotypic immunologic assessment. Am J Trop Med Hyg 2000;62:57-64.
127. Correa-Oliveira R, Caldas IR, Gazzinelli G. Natural versus drug-induced resistance in Schistosoma mansoni infection. Parasitol Today 2000;16:397-399.
128. Brito CF, Caldas IR, Coura Filho P, Correa-Oliveira R, Oliveira SC. CD4+ T cells of schistosomiasis naturally resistant individuals living in an endemic area produce interferon-gamma and tumour necrosis factor-alpha in response to the recombinant 14 kDa Schistosoma mansoni fatty acid-binding protein. Scand J Immunol 2000;51:595-601.
129. Hewitson JP, Hamblin PA, Mountford AP. Immunity induced by the radiation-attenuated schistosome vaccine. Parasite Immunol 2005;27:271-280.
130. Bickle QD, James ER. Resistance against Schistosoma mansoni induced by immunization of mice with cryopreserved schistosomula. Trans R Soc Trop Med Hyg 1978;72:677-678.
131. Minard P, Dean DA, Jacobson RH, Vannier WE, Murrell KD. Immunization of mice with cobalt-60 irradiated Schistosoma mansoni cercariae. Am J Trop Med Hyg 1978;27:76-86.
132. Murrell KD, Clark S, Dean DA, Vannier WE. Influence of mouse strain on induction of resistance with irradiated Schistosoma mansoni cercariae. J Parasitol 1979;65:829-831.
133. Hsu SY, Hsu HF, Burmeister LF. Schistosoma mansoni: vaccination of mice with highly x-irradiated cercariae. Exp Parasitol 1981;52:91-104.
134. Agnew AM, Murare HM, Doenhoff MJ. Specific cross-protection between Schistosoma bovis and S. haematobium induced by highly irradiated infections in mice. Parasite Immunol 1989;11:341-349.
135. Anderson S, Shires VL, Wilson RA, Mountford AP. In the absence of IL-12, the induction of Th1-mediated protective immunity by the attenuated schistosome vaccine is impaired, revealing an alternative pathway with Th2-type characteristics. Eur J Immunol 1998;28:2827-2838.
136. Dean DA, Mangold BL, Harrison RA, Ricciardone MD. Homologous and heterologous protective immunity to Egyptian strains of Schistosoma mansoni and S. haematobium induced by ultraviolet-irradiated cercariae. Parasite Immunol 1996;18:403-410.
137. Ruppel A, Shi YE, Moloney NA. Schistosoma mansoni and S. japonicum: comparison of levels of ultraviolet irradiation for vaccination of mice with cercariae. Parasitology 1990;101:23-26.
138. Ford MJ, Bickle QD, Taylor MG. Immunization of rats against Schistosoma mansoni using irradiated cercariae, lung schistosomula and liver-stage worms. Parasitology 1984;89:327-344.
139. Soisson LA, Reid GD, Farah IO, Nyindo M, Strand M. Protective immunity in baboons vaccinated with a recombinant antigen or radiation-attenuated cercariae of Schistosoma mansoni is antibody-dependent. J Immunol 1993;151:4782-4789.
140. Yole DS, Pemberton R, Reid GD, Wilson RA. Protective immunity to Schistosoma mansoni induced in the olive baboon Papio anubis by the irradiated cercaria vaccine. Parasitology 1996;112:37-46.
141. Harrison RA, et al. Immunization of baboons with attenuated schistosomula of Schistosoma haematobium: levels of protection induced by immunization with larvae irradiated with 20 and 60 krad. Trans R Soc Trop Med Hyg 1990;84:89-99.
142. Bergquist NR, Colley DG. Schistosomiasis vaccine: research to development. Parasitol Today 1998;14:99-104.
143. Al-Sherbiny M, Osman A, Barakat R, El Morshedy H, Bergquist R, Olds R. In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens. Acta Trop 2003;88:117-130.
144. Ribeiro de Jesus A, et al. Human immune responses to Schistosoma mansoni vaccine candidate antigens. Infect Immun 2000;68: 2797-2803.
145. Capron A, Capron M, Dombrowicz D, Riveau G. Vaccine strategies against schistosomiasis: from concepts to clinical trials. Int Arch Allergy Immunol 2001;124:9-15.
146. Capron A, Riveau G, Capron M, Trottein F. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol 2005;21:143-149.
147. Moser D, Tendler M, Griffiths G, Klinkert MQ. A 14-kDa Schistosoma mansoni polypeptide is homologous to a gene family of fatty acid binding proteins. J Biol Chem 1991;266:8447-8454.
148. Tendler M, Simpson AJ. The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine. Acta Trop 2008;108:263-266.
149. Ramos CR, et al. Stability improvement of the fatty acid binding protein Sm14 from S. mansoni by Cys replacement: structural and functional characterization of a vaccine candidate. Biochim Biophys Acta 2009;1794:655-662.
150. Ahmad G, Torben W, Zhang W, Wyatt M, Siddiqui AA. Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni. Parasite Immunol 2009;31:156-161.
151. Ahmad G, et al. Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine 2009;27:2830-2837.
152. Ahmad G, et al. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res 2009;105:1767-1777.
153. Verjovski-Almeida S, et al. Transcriptome analysis of the acoelomate human parasite Schistosoma mansoni. Nat Genet 2003;35:148-157.
154. Berriman M, et al. The genome of the blood fluke Schistosoma mansoni. Nature 2009;460:352-358.
155. Schistosoma japonicum Genome Sequencing and Functional Analysis Consortium. The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature 2009;460:345-351.
156. Knudsen GM, Medzihradszky KF, Lim KC, Hansell E, McKerrow JH. Proteomic analysis of Schistosoma mansoni cercarial secretions. Mol Cell Proteomics 2005;4:1862-1875.
157. van Balkom BW, et al. Mass spectrometric analysis of the Schistosoma mansoni tegumental sub-proteome. J Proteome Res 2005;4:958-966.
158. Braschi S, Wilson RA. Proteins exposed at the adult schistosome surface revealed by biotinylation. Mol Cell Proteomics 2006;5:347-356.
159. Braschi S, Curwen RS, Ashton PD, Verjovski-Almeida S, Wilson A. The tegument surface membranes of the human blood parasite Schistosoma mansoni: a proteomic analysis after differential extraction. Proteomics 2006;6:1471-1482.
160. Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat Rev Immunol 2002;2:499-511.
161. Loukas A, Tran M, Pearson MS. Schistosome membrane proteins as vaccines. Int J Parasitol 2007;37:257-263.
162. Willadsen P, et al. Immunologic control of a parasitic arthropod identification of a protective antigen from Boophilus microplus. J Immunol 1989;143:1346-1351.
163. Willadsen P. The molecular revolution in the development of vaccines against ectoparasites. Vet Parasitol 2001;101:353-368.
164. Smith TS, Munn EA, Graham M, Tavernor AS, Greenwood CA. Purification and evaluation of the integral membrane protein H11 as a protective antigen against Haemonchus contortus. Int J Parasitol 1993;23:271-280.
165. Johnson KS, et al. Vaccination against ovine cysticercosis using a defined recombinant antigen. Nature 1989;338:585-587.
166. Lightowlers MW, et al. Vaccination against hydatidosis using a defined recombinant antigen. Parasite Immunol 1996;18:457-462.
167. Jazwinski SM, Chen JB, Sun J. A single gene change can extend yeast life span: the role of Ras in cellular senescence. Adv Exp Med Biol 1993;330:45-53.
168. Smyth D, McManus DP, Smout MJ, Laha T, Zhang W, Loukas A. Isolation of cDNAs encoding secreted and transmembrane proteins from Schistosoma mansoni by a signal sequence trap method. Infect Immun 2003;71:2548-2554.
169. Tran MH, et al. Suppression of mRNAs encoding tegument tetraspanins from Schistosoma mansoni results in impaired tegument turnover. PLoS Pathog 2010;6:e1000840.
170. Da'dara AA, et al. DNA-based vaccines protect against zoonotic schistosomiasis in water buffalo. Vaccine 2008;26:3617-3625.
171. Sciutto E, et al. Renewed hope for a vaccine against the intestinal adult Taenia solium. J Parasitol 2007;93:824-831.
172. Zhang W, McManus DP. Vaccination of dogs against Echinococcus granulosus: a means to control hydatid disease? Trends Parasitol 2008;24:419-424.
173. Lightowlers MW, Mitchell GF, Rickard MD. Cestodes. In: Warren KS, Agabian N eds. Immunology and Molecular Biology of Parasitic Infections. Cambridge: Blackwell Scientific, 1993:438-472.
174. Miller HM. Jr, Gardiner ML. Passive immunity to infection with a metazoan parasite, Cysticercus fasciolaris, in the albino rat. J Prev Med 1932;6:479-496.
175. Lightowlers MW. Fact or hypothesis: concomitant immunity in taeniid cestode infections. Parasite Immunol. 2010;32:582-589.
176. Rickard MD, Williams JF. Hydatidosis/cysticercosis: immune mechanisms and immunization against infection. Adv Parasitol 1982;21:229-296.
177. Mitchell GF, Rajasekariah GR, Rickard MD. A mechanism to account for mouse strain variation in resistance to the larval cestode, Taenia taeniaeformis. Immunology 1980;39:481-489.
178. Musoke AJ, Williams JF. Immunoglobulins associated with passive transfer of resistance to Taenia taeniaeformis in the mouse. Immunology 1975;28:97-101.
179. Lightowlers MW, Gemmell MA, Harrison GBL, Heath DD, Rickard MD, Roberts MG. Control of tissue parasites. II. Cestodes. In: Yong WK ed. Animal Parasite Control Utilizing Biotechnology. Boca Raton: CRC Press, Inc, 1992:171-198.
180. Musoke AJ, Williams JF. The immunological response of the rat to infection with Taenia taeniaeformis V. Sequence of appearance of protective immunoglobulins and the mechanism of action of 7Sgamma2a antibodies. Immunology 1975;29:855-866.
181. Mitchell GF, Goding JW, Rickard MD. Studies on immune responses to larval cestodes in mice. Increased susceptibility of certain mouse strains and hypothymic mice to Taenia taeniaeformis and analysis of passive transfer of resistance with serum. Aust J Exp Biol Med Sci 1977;55:165-186.
182. Miller HM Jr. Specific immune serums as inhibitors of infections of a metazoan parasite (Cysticercus fasciolaris). Am J Hyg 1934;19:270-277.
183. Miller HM. The production of artificial immunity in the albino rat to a metazoan parasite. J Prev Med 1931;5:429-452.
184. Rajasekariah GR, Mitchell GF, Rickard MD. Taenia taeniaeformis in mice protective immunization with oncospheres and their products. Int J Parasitol 1980;10:155-160.
185. Harrison GB, et al. Identification and cDNA cloning of two novel low molecular weight host-protective antigens from Taenia ovis oncospheres. Int J Parasitol 1996;26:195-204.
186. Cox FEG. Milestones in parasitology. Parasitol Today 1993;9:347-348.
187. Silverman PH. A technique for studying the in vitro effect of serum on activated taeniid hexacanth embryos. Nature 1955;176:598-599.
188. Heath DD, Smyth JD. In vitro cultivation of Echinococcus granulosus, Taenia hydatigena, T. ovis, T. pisiformis and T. serialis from oncosphere to cystic larva. Parasitology 1970;61:329-343.
189. Heath DD, Lawrence SB. Echinococcus granulosus cysts: early development in vitro in the presence of serum from infected sheep. Int J Parasitol 1981;11:261-266.
190. Kyngdon CT, et al. In vitro oncosphere-killing assays to determine immunity to the larvae of Taenia pisiformis, Taenia ovis, Taenia saginata, and Taenia solium. J Parasitol 2006;92:273-281.
191. Lightowlers MW, et al. Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep. Int J Parasitol 1999;29:531-534.
192. Gonzalez AE, et al. Vaccination of pigs to control human neurocysticercosis. Am J Trop Med Hyg 2005;72:837-839.
193. Flisser A, et al. Induction of protection against porcine cysticercosis by vaccination with recombinant oncosphere antigens. Infect Immun 2004;72:5292-5297.
194. Assana E, et al. Elimination of Taenia solium transmission to pigs in a field trial of the TSOL18 vaccine in Cameroon. Int J Parasitol 2010;40:515-519.
195. Lightowlers MW. Eradication of Taenia solium cysticercosis: a role for vaccination of pigs. Int J Parasitol. 2010;40:1183-1192.
196. Schantz PM, Cruz M, Sarti E, Pawlowski Z. Potential eradicability of taeniasis and cysticercosis. Bull Pan Am Health Organ 1993;27:397-403.
197. Freedman DO, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006;354:119-130.
198. Haque R, et al. Prospective case-control study of the association between common enteric protozoal parasites and diarrhea in Bangladesh. Clin Infect Dis 2009;48:1191-1197.
199. Ng CT, Gilchrist CA, Lane A, Roy S, Haque R, Houpt ER. Multiplex real-time PCR assay using Scorpion probes and DNA capture for genotype-specific detection of Giardia lamblia on fecal samples. J Clin Microbiol 2005;43:1256-1260.
200. Davids BJ, et al. A new family of giardial cysteine-rich non-VSP protein genes and a novel cyst protein. PLoS One 2006;1:e44.
201. Lee P, Abdul-Wahid A, Faubert GM. Comparison of the local immune response against Giardia lamblia cyst wall protein 2 induced by recombinant Lactococcus lactis and Streptococcus gordonii. Microbes Infect 2009;11:20-28.
202. Rivero FD, Saura A, Prucca CG, Carranza PG, Torri A, Lujan HD. Disruption of antigenic variation is crucial for effective parasite vaccine. Nat Med 2010;16:551-557.
203. Chen XM, Keithly JS, Paya CV, LaRusso NF. Cryptosporidiosis. N Engl J Med 2002;346:1723-1731.
204. Carmolli M, et al. Deficient serum mannose-binding lectin levels and MBL2 polymorphisms increase the risk of single and recurrent Cryptosporidium infections in young children. J Infect Dis 2009;200:1540-1547.
205. Kirkpatrick BD, et al. Association between Cryptosporidium infection and human leukocyte antigen class I and class II alleles. J Infect Dis 2008;197:474-478.
206. White AC Jr. Nitazoxanide: an important advance in anti-parasitic therapy. Am J Trop Med Hyg 2003;68:382-383.
207. Benitez AJ, McNair N, Mead JR. Oral immunization with attenuated Salmonella enterica serovar Typhimurium encoding Cryptosporidium parvum Cp23 and Cp40 antigens induces a specific immune response in mice. Clin Vaccine Immunol 2009;16:1272-1278.
208. Jenkins MC. Present and future control of cryptosporidiosis in humans and animals. Expert Rev Vaccines 2004;3:669-671.
209. O'Connor RM, et al. Polymorphic mucin antigens CpMuc4 and CpMuc5 are integral to Cryptosporidium parvum infection in vitro. Eukaryot Cell 2009;8:461-469.
210. O'Connor RM, Wanyiri JW, Cevallos AM, Priest JW, Ward HD. Cryptosporidium parvum glycoprotein gp40 localizes to the sporozoite surface by association with gp15. Mol Biochem Parasitol 2007;156:80-83.
211. Haque R, Huston CD, Hughes M, Houpt E, Petri WA Jr. Amebiasis. N Engl J Med 2003;348:1565-1573.
212. WHO. Amoebiasis. Wkly Epidemiol Rec 1997;72:97-99.
213. Caballero-Salcedo A, et al. Seroepidemiology of amebiasis in Mexico. Am J Trop Med Hyg 1994;50:412-419.
214. Braga LL, et al. Seroepidemiology of Entamoeba histolytica in a slum in northeastern Brazil. Am J Trop Med Hyg 1996;55:693-697.
215. Haque R, et al. Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun 2006;74:904-909.
216. Barwick RS, Mohammed HO, McDonough PL, White ME. Epidemiologic features of equine Leptospira interrogans of human significance. Prev Vet Med 1998;36:153-165.
217. Petri WA. Jr, Haque R, Mann BJ. The bittersweet interface of parasite and host: lectin-carbohydrate interactions during human invasion by the parasite Entamoeba histolytica. Annu Rev Microbiol 2002;56:39-64.
218. Boettner DR, et al. Entamoeba histolytica phagocytosis of human erythrocytes involves PATMK, a member of the transmembrane kinase family. PLoS Pathog 2008;4:e8.
219. Haque R, Ali IM, Sack RB, Farr BM, Ramakrishnan G, Petri WA Jr. Amebiasis and mucosal IgA antibody against the Entamoeba histolytica adherence lectin in Bangladeshi children. J Infect Dis 2001;183:1787-1793.
220. Chaudhry OA, Petri WA Jr. Vaccine prospects for amebiasis. Expert Rev Vaccines 2005;4:657-668.
221. Guo X, et al. Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon. Infect Immun 2009;77:3909-3918.
222. Scientific Working Group on Leishmaniasis. Meeting report. 2-4 February 2004, Geneva, Switzerland. Available from.
223. Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 2001;45:2185-2197.
224. Reed SG, Scott P. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 1993;5:524-531.
225. Scott P, Pearce E, Cheever AW, Coffman RL, Sher A. Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev 1989;112:161-182.
226. Sypek JP, et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper Type 1 immune response. J Exp Med 1993;177:1797-1802.
227. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505-1509.
228. Sacks DL, Melby PC. Animal models for the analysis of immune responses to leishmaniasis. Curr Protoc Immunol 2001; Chapter 19:Unit 19 2.
229. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect Immun 2007;75:4648-4654.
230. Coler RN, et al. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 2002;70:4215-4225.
231. Goto Y, et al. Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection. Vaccine 2009;27:2884-2890.
232. Goto Y, Bogatzki LY, Bertholet S, Coler RN, Reed SG. Protective immunization against visceral leishmaniasis using leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 2007;25:7450-7458.
233. Trigo J, et al. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f + MPL-SE. Vaccine 2010;28:3333-3340.
234. Borja-Cabrera GP, et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 2002;20:3277-3284.
235. Borja-Cabrera GP, et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 2004;22: 2234-2243.
236. Greenblatt CL. The present and future of vaccination for cutaneous leishmaniasis. Prog Clin Biol Res 1980;47:259-285.
237. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001;14:229-243.
238. Palatnik-de-Sousa CB. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 2008;26:1709-1724.
239. Badaro R, et al. Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis 2006;194:1151-1159.
240. Badaro R, et al. Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report. Braz J Infect Dis 2001;5:223-232.
241. Reed SG, Coler RN, Campos-Neto A. Development of a leishmaniasis vaccine: the importance of MPL. Expert rev vaccines 2003;2:239-252.
242. Campos-Neto A, et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 2001;69:4103-4108.
243. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. Leish-111f, a Recombinant Polyprotein Vaccine that protects against visceral Leishmaniasis by the elicitation of CD4+ T cells. Infect Immun 2007;75:4648-454.
244. Miret J, et al. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 2008;26:1585-1594.
245. Nascimento E, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 2010;28:6581-6587.
246. Velez ID, et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 2009;28:329-337.
247. Skeiky YA, et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce Interleukin 12. J Exp Med 1995;181:1527-1537.
248. Ribeiro JM, Francischetti IM. Role of arthropod saliva in blood feeding: sialome and post-sialome perspectives. Annu Rev Entomol 2003;48:73-88.
249. Titus RG, Bishop JV, Mejia JS. The immunomodulatory factors of arthropod saliva and the potential for these factors to serve as vaccine targets to prevent pathogen transmission. Parasite Immunol 2006;28:131-141.
250. Andrade BB, de Oliveira CI, Brodskyn CI, Barral A, Barral-Netto M. Role of sand fly saliva in human and experimental leishmaniasis: current insights. Scand J Immunol 2007;66:122-127.
251. Schneider BS, Higgs S. The enhancement of arbovirus transmission and disease by mosquito saliva is associated with modulation of the host immune response. Trans R Soc Trop Med Hyg 2008;102: 400-408.
252. Oliveira F, Jochim RC, Valenzuela JG, Kamhawi S. Sand flies, Leishmania, and transcriptome-borne solutions. Parasitol Int 2009;58:1-5.
253. Mejia JS, Bishop JV, Titus RG. Is it possible to develop pan-arthropod vaccines? Trends Parasitol 2006;22:367-370.
254. Titus RG, Ribeiro JM. Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 1988;239:1306-1308.
255. Belkaid Y, et al. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 1998;188:1941-1953.
256. Volfova V, Hostomska J, Cerny M, Votypka J, Volf P. Hyaluronidase of bloodsucking insects and its enhancing effect on leishmania infection in mice. PLoS Negl Trop Dis. 2008;2:e294.
257. Mesquita RD, et al. Trypanosoma cruzi infection is enhanced by vector saliva through immunosuppressant mechanisms mediated by lysophosphatidylcholine. Infect Immun 2008;76:5543-5552.
258. Caljon G, Van Den Abbeele J, Sternberg JM, Coosemans M, De Baetselier P, Magez S. Tsetse fly saliva biases the immune response to Th2 and induces anti-vector antibodies that are a useful tool for exposure assessment. Int J Parasitol 2006;36:1025-1035.
259. Caljon G, Van Den Abbeele J, Stijlemans B, Coosemans M, De Baetselier P, Magez S. Tsetse fly saliva accelerates the onset of Trypanosoma brucei infection in a mouse model associated with a reduced host inflammatory response. Infect Immun 2006;74:6324-6330.
260. Zeidner NS, Higgs S, Happ CM, Beaty BJ, Miller BR. Mosquito feeding modulates Th1 and Th2 cytokines in flavivirus susceptible mice: an effect mimicked by injection of sialokinins, but not demonstrated in flavivirus resistant mice. Parasite Immunol 1999;21:35-44.
261. Schneider BS, Soong L, Zeidner NS, Higgs S. Aedes aegypti salivary gland extracts modulate anti-viral and TH1/TH2 cytokine responses to sindbis virus infection. Viral Immunol 2004;17:565-573.
262. Boppana VD, Thangamani S, Adler AJ, Wikel SK. SAAG-4 is a novel mosquito salivary protein that programmes host CD4 T cells to express IL-4. Parasite Immunol 2009;31:287-295.
263. Tsujimoto H, Gray EW, Champagne DE. Black fly salivary gland extract inhibits proliferation and induces apoptosis in murine splenocytes. Parasite Immunol 2010; 32:275-284.
264. Morris RV, Shoemaker CB, David JR, Lanzaro GC, Titus RG. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol 2001;167:5226-5230.
265. Ribeiro JM, et al. An annotated catalogue of salivary gland transcripts in the adult female mosquito, Aedes aegypti. BMC Genomics 2007;8:6.
266. Andersen JF, Pham VM, Meng Z, Champagne DE, Ribeiro JM. Insight into the sialome of the Black Fly, Simulium vittatum. J Proteome Res 2009;8:1474-1488.
267. Alves-Silva J, et al. An insight into the sialome of Glossina morsitans morsitans. BMC Genomics 2010; 11:213.
268. de Moura TR, et al. Enhanced Leishmania braziliensis infection following pre-exposure to sandfly saliva. PLoS Negl Trop Dis 2007;1:e84.
269. Valenzuela JG, et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med 2001;194:331-342.
270. Oliveira F, Lawyer PG, Kamhawi S, Valenzuela JG. Immunity to distinct sand fly salivary proteins primes the anti-Leishmania immune response towards protection or exacerbation of disease. PLoS Negl Trop Dis 2008;2:e226.
271. Marsollier L, et al. Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. PLoS Med 2007;4:e64.
272. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002;2:845-858.
273. Okwor I, Uzonna J. Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Immunol Res 2008;41:123-136.
274. Kamhawi S, Belkaid Y, Modi G, Rowton E, Sacks D. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 2000;290:1351-1354.
275. Thiakaki M, Rohousova I, Volfova V, Volf P, Chang KP, Soteriadou K. Sand fly specificity of saliva-mediated protective immunity in Leishmania amazonensis-BALB/c mouse model. Microbes Infect 2005;7:760-766.
276. Vinhas V, et al. Human anti-saliva immune response following experimental exposure to the visceral leishmaniasis vector, Lutzomyia longipalpis. Eur J Immunol 2007;37:3111-3121.
277. Gomes R, et al. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci U S A 2008;105:7845-7850.
278. Oliveira F, et al. From transcriptome to immunome: identification of DTH inducing proteins from a Phlebotomus ariasi salivary gland cDNA library. Vaccine 2006;24:374-390.
279. Collin N, et al. Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania. PLoS Pathog 2009;5:e1000441.
280. Hotez PJ. The neglected tropical diseases and their devastating health and economic impact on the member nations of the Organisation of the Islamic Conference. PLoS Negl Trop Dis 2009;3:e539.
281. Hotez PJ. Peace through vaccine diplomacy. Science 2010;327:1301.
282. Mahoney RT, Maynard JE. The introduction of new vaccines into developing countries. Vaccine 1999;17:646-652.
283. Moran M, Guzman J, Ropars AL, Illmer A. The role of product development partnerships in research and development for negelcted diseases. Int Health 2010;2:114-122.
284. Morel CM, et al. Health innovation networks to help developing countries address neglected diseases. Science 2005;309:401-404.
285. Watson M, Shaw D, Molchanoff L, McInnes C. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust N Z J Public Health 2009;33:365-370.
286. Andrus JK, de Quadros C, Matus CR, Luciani S, Hotez P. New vaccines for developing countries: will it be feast or famine? Am J Law Med 2009;35:311-322.
287. Molyneux DH, Hotez PJ, Fenwick A. "Rapid-impact interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med 2005;2:e336.